NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced.
Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline
News provided by
Share this article
Share this article
NEW YORK, Feb. 2, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications.
Drug Pipeline Highlights:
HT-001: Granted Pre-IND meeting with FDA with responses targeted for February 22, 2021
HT-003: Received positive preclinical mechanism of action date for acne treatment and renewal of the preclinical research plan
HT-004: Key proof-of-concept animal model data expected in Q2 2021
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, Hoth s entire pipeline of innovative novel therapeutics have made significant progress throughout their developmental process over the course of the last year. During that time, we have been able to strengthen our balance shee